A Complimentary Continuing Education Lecture Series for Healthcare
HADDON HEIGHTS, N.J., March 24 /PRNewswire/ -- Glioblastomas are the most common and most malignant type of glioma. Healthcare professionals face many challenges in the treatment of glioblastoma as therapy remains largely palliative, and mean length of survival in patients is less than one year.
Recent clinical trials have shown that combining surgery, radiation therapy and chemotherapy extends survival in a subset of patients, particularly when the chemotherapeutic agent temozolomide is included in the treatment approach. Other potentially promising therapies for glioblastoma under investigation include regional drug administration, targeted biological therapies, vaccines, and genomic profiling. As research continues, new agents for adult glioblastoma are expected to further extend survival.
To address the need for current education on glioblastoma, treatment strategies, challenges, and emerging therapies, Robert Michael Educational Institute LLC and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a series of complimentary live educational lectures in institutions across the United States, as well as an online educational activity consisting of a virtual lecture presentation.
The Course Director for this continuing education opportunity is Dr. Marc C. Chamberlain, Professor of Neurology at the University of Washington and expert in the development of clinical trials for primary brain tumors. All lectures will be presented by experts in the treatment of glioblastoma. Continuing education credit will be offered for physicians, pharmacists and nurses.
Healthcare professionals can schedule a live lecture at their
institution by contacting RMEI:
Toll-free Phone: 1-866-770-7634, ext.
|SOURCE Robert Michael Educational Institute LLC|
Copyright©2008 PR Newswire.
All rights reserved